Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

PR-220

Alternative Names: pr-220, prs220, prs 220
Latest Update: 2022-06-20
Latest Update Note: Clinical Trial Update

Product Description

PRS-220 is an oral inhaled Anticalin protein targeting connective tissue growth factor (CTGF), also known as CCN2, for the treatment of idiopathic pulmonary fibrosis (IPF). (Sourced from: https://www.pieris.com/pipeline/prs-220)

Mechanisms of Action: CTGF Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral,Inhalant

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pieris
Company Location: BOSTON MA 02109
Company CEO: Stephen S. Yoder
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Idiopathic Pulmonary Fibrosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions